曲妥珠单抗联合帕妥珠单抗治疗HER2扩增的晚期结直肠癌:药物再发现方案(DRUP)结果
在药物再发现方案(DRUP)中,对RAS/BRAF野生型HER2扩增的难治性转移性结直肠癌患者给予曲妥珠单抗联合帕妥珠单抗治疗,24例可评估患者中11例(46%)获得临床获益,7例(29%)达到客观缓解,中位缓解持续时间8.4个月,未观察到意外毒性。
要点
- 曲妥珠单抗联合帕妥珠单抗在HER2扩增转移性结直肠癌中临床获益率46%(11/24),客观缓解率29%(7/24)。
- 中位无进展生存期4.3个月(95%CI 1.9-10.3),中位总生存期8.2个月(95%CI 7.2-14.7)。
- 中位缓解持续时间8.4个月,未观察到意外毒性。
核心结论
- 本研究结果证实曲妥珠单抗联合帕妥珠单抗治疗在HER2扩增转移性结直肠癌患者中具有临床显著获益。
研究设计与样本
- 药物再发现方案(DRUP)为基于分子谱给予超适应症药物治疗的方案,本研究为其「曲妥珠单抗/帕妥珠单抗用于RAS/BRAF野生型HER2扩增转移性结直肠癌难治性患者」队列。
- 纳入进展期、治疗难治、RAS/BRAF野生型、HER2扩增、有可测量病灶的转移性结直肠癌患者,接受曲妥珠单抗联合帕妥珠单抗治疗。
- 主要终点为临床获益(定义为确认的客观缓解或稳定疾病≥16周)和安全性;采用类Simon两阶段模型入组,第一阶段8例,若至少1/8患者获得临床获益则进入第二阶段24例。
- 对治疗前活检组织进行全基因组测序以识别缓解生物标志物。
主要发现
- 24例可评估的HER2扩增转移性结直肠癌患者中,11例(46%)获得临床获益,7例(29%)达到客观缓解。
- 中位缓解持续时间为8.4个月。
- 患者既往中位治疗线数为3线。
- 中位无进展生存期为4.3个月(95%CI 1.9-10.3),中位总生存期为8.2个月(95%CI 7.2-14.7)。
- 未观察到意外毒性;在10例无临床获益且可行全基因组测序的患者中,3例的全基因组测序为耐药提供了可能解释。
关键数值与推荐
- 临床获益定义为确认的客观缓解或稳定疾病≥16周。
- 24例可评估患者中临床获益11例(46%),客观缓解7例(29%)。
- 中位缓解持续时间8.4个月;中位无进展生存期4.3个月(95%CI 1.9-10.3);中位总生存期8.2个月(95%CI 7.2-14.7)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In 2-5% of patients with colorectal cancer (CRC), human epidermal growth factor 2 (HER2) is amplified or overexpressed. Despite prior evidence that anti-HER2 therapy confers clinical benefit (CB) in one-third of these patients, it is not approved for this indication in Europe. In the Drug Rediscovery Protocol (DRUP), patients are treated with off-label drugs based on their molecular profile. Here, we present the results of the cohort 'trastuzumab/pertuzumab for treatment-refractory patients with RAS/BRAF-wild-type HER2amplified metastatic CRC (HER2+mCRC)'. METHODS: Patients with progressive treatment-refractory RAS/BRAF-wild-type HER2+mCRC with measurable disease were included for trastuzumab plus pertuzumab treatment. Primary endpoints of DRUP are CB (defined as confirmed objective response (OR) or stable disease (SD) ≥ 16 weeks) and safety. Patients were enrolled using a Simon-like 2-stage model, with 8 patients in stage 1 and 24 patients in stage 2 if at least 1/8 patients had CB. To identify biomarkers for response, whole genome sequencing (WGS) was performed on pre-treatment biopsies. RESULTS: CB was observed in 11/24 evaluable patients (46%) with HER2+mCRC, seven patients achieved an OR (29%). Median duration of response was 8.4 months. Patients had undergone a median of 3 prior treatment lines. Median progression-free survival and overall survival were 4.3 months (95% CI 1.9-10.3) and 8.2 months (95% CI 7.2-14.7), respectively. No unexpected toxicities were observed. WGS provided potential explanations for resistance in 3/10 patients without CB, for whom WGS was available. CONCLUSIONS: The results of this study confirm a clinically significant benefit of trastuzumab plus pertuzumab treatment in patients with HER2+mCRC.
引用
- Spiekman IAC, Zeverijn LJ, Geurts BS, et al. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP). Eur J Cancer. 2024. PMID: 38471288. doi:10.1016/j.ejca.2024.113988
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。